PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

PVI, PeerView Institute for Medical Education

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

All episodes

Best episodes

Top 10 PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast Episodes

Goodpods has curated a list of the 10 best PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast episode by adding your comments to the episode page.

James R. Gavin III, MD, PhD - Swimming in Cloudy Water: Using the Latest Guidelines to Clear Up Clinical Confusion About T2DM Management

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

09/04/19 • 72 min

Go online to PeerView.com/ASM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in primary care, endocrinology, and diabetes education offer insights on providing patient-centered diabetes care and developing individualized treatment plans for patients with type 2 diabetes mellitus (T2DM). Upon completion of this activity, participants should be better able to: Reconcile recommendations offered in evidence-based clinical guidelines focusing on individualized management of type 2 diabetes mellitus (T2DM), Identify and assess patient factors and health status to appropriately individualize glycemic targets and antihyperglycemic therapy in patients with T2DM, Acknowledge the preferred role and placement of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT2) inhibitors in current T2DM treatment algorithms.

John B. Buse, MD, PhD - An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Disease in Patients With Type 2 Diabetes

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

07/05/19 • 40 min

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Sumanta Kumar Pal, MD, FASCO - Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the Disease Spectrum

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

07/05/23 • 83 min

Go online to PeerView.com/DGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovation in renal cell carcinoma (RCC) has brought new opportunities to improve patient outcomes through personalized medicine. With multiple FDA approvals and promising agents being explored in a variety of settings, multitargeted TKIs and immune checkpoint inhibitors have earned their place in cancer care plans either as guideline-recommended therapy or through clinical trial enrollment. In this activity, which was based on a recent live event, a panel of expert oncologists combines a concise overview of essential research on approved and emerging RCC treatments with discussion of real-life patient cases to provide guidance on integrating validated strategies into everyday patient care. Learn how patient-, disease-, and treatment-specific factors affect therapeutic selection and sequencing—including when to consider adjuvant therapy, which patients may benefit from immunotherapy-based combination regimens in the frontline setting, and how to determine which strategies to recommend for patients with relapsed disease. Hear guidance on collaborative approaches to managing adverse events, insights on the use of emerging agents, and updates on clinical trials underway. Upon completion of this activity, participants should be better able to: Evaluate treatment efficacy and safety of approved and emerging therapeutic regimens for patients with RCC; Select personalized therapeutic strategies based on current evidence and patient-, disease-, and treatment-specific factors for patients with RCC; and Integrate strategies to anticipate, mitigate, and manage various adverse events associated with treatments for patients with RCC

David M. O'Malley, MD - Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evidence Into Meaningful Improvements in Patient Outcomes Across the Disease Continuum

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

07/05/23 • 82 min

Go online to PeerView.com/UDV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While recurrent or advanced endometrial cancer (EC) has traditionally been associated with a poor prognosis, the use of immune checkpoint inhibition (ICI) in both monotherapy and combination approaches has led to improved outcomes. These gains have been well established in the second-line setting with multiple regulatory approvals, and ICIs have recently been shown to have an impact in the frontline setting, further altering the standard of care. In this activity, based on a recent live symposium, a panel of experts provides participants with foundational knowledge on the mechanistic rationale and up-to-date evidence supporting the use of ICIs in patients with advanced EC. Through discussion of real-life patient cases, the faculty provides practical guidance on incorporating approved and emerging approaches into clinical practice. Featured topics include biomarker testing, clinical trial enrollment, patient/provider education, and management of immune-related adverse events. Upon completion of this activity, participants should be better able to: Cite the rationales, therapeutic roles, and key efficacy/safety evidence supporting the use of immuno-oncology treatments and emerging approaches for patients with recurrent or advanced endometrial cancer; Select personalized treatment options for patients with recurrent or advanced endometrial cancer, taking into consideration the latest evidence, guideline recommendations, and biomarker testing results; and Implement proactive, collaborative strategies to mitigate and manage immune-related adverse events associated with immunotherapy-based treatment

Bradley J. Monk, MD, FACS, FACOG - The ABCs of ADCs for Gynecologic Cancer: Expert Insights on Effective Implementation and Practical Tips for Use in Patients With Cervical, Ovarian, or Endometrial Cancer

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

12/13/23 • 40 min

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BVX865. CME/MOC/AAPA/IPCE credit will be available until December 10, 2024.

The ABCs of ADCs for Gynecologic Cancer: Expert Insights on Effective Implementation and Practical Tips for Use in Patients With Cervical, Ovarian, or Endometrial Cancer

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Eisai Inc., and Seagen and Genmab.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Bradley J. Monk, MD, FACS, FACOG, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acrivon Therapeutics; Adaptimmune Therapeutics plc.; Agenus Inc.; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; AstraZeneca; Bayer Corporation; Clovis Oncology; Eisai Inc.; Elevar, LLC; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Genmab A/S/Seagen Inc.; The GOG Foundation Inc; Gradalis, Inc.; ImmunoGen, Inc.; Iovance Biotherapeutics, Inc.; Jiangsu Hengrui Pharmaceuticals Co., Ltd.; Karyopharm; Laekna Therapeutics; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Novocure GmbH; OncoC4, Inc.; Panavance Therapeutics Inc.; Pfizer; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; Sorrento Therapeutics, Inc.; TESARO, Inc./GlaxoSmithKline; US Oncology Research, LLC; VBL Therapeutics; Verastem, Inc.; and Zentalis Pharmaceuticals.
Grant/Research Support from US Oncology Research, LLC.
Speaker for AstraZeneca; Clovis Oncology; Eisai Inc.; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Merck & Co., Inc.; and TESARO, Inc./GlaxoSmithKline.

Faculty/Planner
Ana Oaknin, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agenus Inc.; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera Pharmaceuticals; Eisai Co., Ltd.; EMD Serono; Exelisis, Inc.; F. Hoffmann-La Roche; Genmab A/S; GlaxoSmithKline; ImmunoGen, Inc.; iTeos Therapeutics; Merck Sharp & Dohme de Espana SA; Mersana Therapeutics; Novocure GmbH; OncXerna Therapeutics, Inc.; Pharma Mar SA; Regeneron Pharmaceuticals Inc.; Seagen, Inc.; Shattuck Labs, Inc.; and Sutro Biopharma, Inc.
Grant/Research Support from AbbVie Deutschland; Advaxis Inc.; Aeterna Zentaris; Amgen Inc.; Aprea Therapeutics AB; Bristol Myers Squibb; Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche; ImmunoGen, Inc.; Merck Sharp & Dohme de Espana SA; Millennium Pharmaceuticals Inc.; Pharma Mar SA; Regeneron Pharmaceuticals Inc; and Tesaro.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Benjamin M. Brucker, MD - Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

06/29/23 • 57 min

Go online to PeerView.com/QGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Overactive bladder is frequently underdiagnosed and undertreated, but fortunately there's a newer treatment option with the beta-3 adrenoreceptor agonists. This class demonstrates efficacy without anticholinergic adverse effects, enabling you to provide optimal, patient-centered care for residents of long-term care facilities. This PeerView educational activity is designed to help improve your ability to accurately recognize overactive bladder, apply appropriate diagnostic criteria, and incorporate newer treatment options. Expert faculty explain the clinically relevant ways in which the newer beta-3 adrenoreceptor agonists differ from traditional antimuscarinics, as well as how they differ from each other with regard to selectivity and safety. Upon completion of this activity, participants should be better able to: Recognize the individual, clinical, and economic burdens of OAB specific to patients living in long-term care facilities; Engage members of the healthcare team to routinely screen long-term care residents for symptoms of OAB; Apply recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomatology; and Implement individualized OAB treatment plans that minimize risks related to cardiovascular health, cognitive impairment and dementia, and polypharmacy concerns.

David F. McDermott, MD - Redefining the Management of Advanced RCC: An Expert Tumor Board on Rational Selection, Sequencing, and Combination of Targeted Agents and Immunotherapy

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

07/26/19 • 67 min

Go online to PeerView.com/FPP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, recorded from a live event at the 2019 American Society of Clinical Oncology Annual Meeting, a panel of kidney cancer experts offers case-centric discussion of key evidence that supports clinical decision-making through multiple lines of therapy in advanced RCC, as well as practical instruction on how to effectively and safely integrate novel targeted and immunotherapeutic strategies in an increasingly complex RCC treatment landscape. Upon completion of this activity, participants should be better able to: Summarize the latest evidence and ongoing investigations with novel approaches, including new multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combination therapies, in advanced renal cell carcinoma (RCC), Select optimal frontline treatment options among TKIs and combination approaches (dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors) for individual patients with advanced RCC based on relevant patient- and disease-related characteristics, including in the context of clinical trial enrollment, Recommend targeted agents and immune checkpoint inhibitors optimally to patients with pretreated advanced RCC through multiple lines of therapy, with considerations of prior treatment history and patient comorbidities, Employ effective strategies to prevent and/or manage treatment-related complications with multitargeted TKIs and immune checkpoint inhibitor therapy in patients with RCC.

Elizabeth A. Stewart, MD - Advances in Medical Options for Uterine Fibroids and Endometriosis: Clinical Highlights From Montreal

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

07/15/19 • 30 min

Go online to PeerView.com/NNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in gynecology/obstetrics discusses emerging data on options for the treatment of endometriosis and uterine fibroids that were presented at the 5th Congress of the Society for Endometriosis and Uterine Disorders (SEUD 2019) in Montreal in May 2019. Upon completion of this activity, participants should be better able to: Discuss the latest clinical data on current and emerging treatment options for management of endometriosis, endometriosis-associated pain, and uterine fibroids, Employ recent evidence on new and established treatment approaches for individualized therapeutic management of patients with endometriosis and uterine fibroids.

Adrian Hernandez, MD, MHS - Recognizing and Treating Iron Deficiency in Patients With Heart Failure: Achieving Better Outcomes and Quality of Life

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

07/01/19 • 17 min

Go online to PeerView.com/FCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in cardiology shares insight on recognizing and treating iron deficiency in patients with heart failure to achieve better outcomes and quality of life. Upon completion of this activity, participants should be better able to: Recognize the prevalence of iron deficiency (ID) in heart failure (HF) and its impact on patient outcomes and quality of life, Identify evidence-based guidelines and the latest clinical data on the efficacy and safety of currently available and emerging iron therapies for the management of ID in patients with HF, Apply evidence-based guidelines and the latest clinical data on available and emerging iron therapies to the treatment of ID in patients with HF.

Neal D. Shore, MD, FACS - Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

01/17/24 • 61 min

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.

Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Neal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.

Faculty/Planner
Sia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.
Grant/Research Support from Janssen Pharmaceuticals, Inc.

Faculty/Planner
Guru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.
Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.

Show more best episodes

FAQ

How many episodes does PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast have?

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast currently has 171 episodes available.

What topics does PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast cover?

The podcast is about Health & Fitness, Cme, Medicine, Podcasts, Nephrology, Science and Medical Education.

What is the most popular episode on PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast?

The episode title 'Arjun Balar, MD - Advancing Bladder Cancer Care With Novel Therapeutics: Where We Are Headed With Immunotherapy, Targeted, and Antibody Options' is the most popular.

What is the average episode length on PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast?

The average episode length on PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast is 60 minutes.

How often are episodes of PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast released?

Episodes of PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast are typically released every 5 days.

When was the first episode of PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast?

The first episode of PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast was released on Feb 19, 2019.

Show more FAQ

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

PVI, PeerView Institute for Medical Education

Top 10 PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast Episodes

FAQ

How many episodes does PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast have?

What topics does PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast cover?

What is the most popular episode on PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast?

What is the average episode length on PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast?

How often are episodes of PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast released?

When was the first episode of PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast?

Comments